Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | MMP7 | P09237 | 3/20 | 0.32 |
| ▸ | MMP12 | P39900 | 3/20 | 0.32 |
| ▸ | MMP13 | P45452 | 3/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825362 | 0.84 | TSHR (0.36) | TSHRALDH1A1SMN1; SMN2MMP1MMP7 | |
| SCHEMBL11652838 | 0.82 | TSHR (0.34) | TSHRALDH1A1SMN1; SMN2MMP1MMP7 | |
| SCHEMBL27289489 | 0.81 | TP53 (0.37) | TSHRSMN1; SMN2MMP1MMP7MMP12 | |
| SCHEMBL3365927 | 0.81 | CA2 (0.36) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL8458904 | 0.81 | MMP1 (0.35) | TSHRALDH1A1SMN1; SMN2MMP1MMP7 | |
| SCHEMBL88231 | 0.81 | TP53 (0.37) | TSHRALDH1A1SMN1; SMN2MMP1MMP7 | |
| Ammonia Solution, Strong SCHEMBL1646990 | 0.79 | TP53 (0.36) | TSHRALDH1A1SMN1; SMN2MMP1MMP7 | |
| SCHEMBL7125310 | 0.79 | MMP1 (0.34) | TSHRALDH1A1SMN1; SMN2MMP1MMP7 | |
| SCHEMBL9514472 | 0.79 | MMP1 (0.34) | TSHRALDH1A1SMN1; SMN2MMP1MMP7 | |
| SCHEMBL14892962 | 0.77 | TP53 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114456181-A | Preparation method of luccotinib | 浙江乐普药业股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| WO-2006095359-A1 | SYNTHESIS OF 2-DEOXY-2, 2-DI FLUORO-D-RIBO FURANOSE-3, 5 DI(4-METHY/4-NITRO-CHLORO)BENZOATE AND ITS CONVERSION TO GEMCITABINE HYDROCHLORIDE THEREOF | SMS PHARMACEUTICALS LIMITED (IN) | 2006-09-14 | — | — | WO | claimed |
| EP-0077330-A4 | EMULSIFYING ADDITIVE FOR OIL BASE DRILLING FLUIDS AND METHOD. | OBI HUGHES INC (US) | 1983-08-24 | — | — | EP | claimed |
| EP-0077330-A1 | EMULSIFYING ADDITIVE FOR OIL BASE DRILLING FLUIDS AND METHOD | OBI-HUGHES, INC. (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003389-A1 | EMULSIFYING ADDITIVE FOR OIL BASE DRILLING FLUIDS AND METHOD | BARTHEL HORST K F | 1982-10-14 | — | — | WO | claimed |
| CN-114456181-A | Preparation method of luccotinib | 浙江乐普药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20190202782-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10315991-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180201577-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20040044025-A1 | Processes for the preparation of antiviral 7-azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003082289-A1 | PROCESS FOR THE PREPARATION OF ANTIVIRAL 7-AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-0712576-A1 | Antifouling agent | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1996-05-22 | — | — | EP | disclosed |
| US-5472483-A | Polysulfide compounds with carriers for protective coating of underwater structures | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1995-12-05 | — | — | US | disclosed |
| EP-0077330-A4 | EMULSIFYING ADDITIVE FOR OIL BASE DRILLING FLUIDS AND METHOD. | OBI HUGHES INC (US) | 1983-08-24 | — | — | EP | disclosed |
| EP-0077330-A1 | EMULSIFYING ADDITIVE FOR OIL BASE DRILLING FLUIDS AND METHOD | OBI-HUGHES, INC. (US) | 1983-04-27 | — | — | EP | disclosed |
| WO-1982003389-A1 | EMULSIFYING ADDITIVE FOR OIL BASE DRILLING FLUIDS AND METHOD | BARTHEL HORST K F | 1982-10-14 | — | — | WO | disclosed |
| US-4101468-A | Process for cold-hardening polyurethane foams using sulfonamide emulsifiers | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044025-A1 | Processes for the preparation of antiviral 7-azaindole derivatives | IMPDH1, MAVS, ZC3HAV1 | TSHR 4520/4885ALDH1A1 498/4885SMN1; SMN2 3419/4885 |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | TSHR 3518/4885ALDH1A1 1089/4885SMN1; SMN2 1176/4885 |
| US-20180201577-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | TSHR 3518/4885ALDH1A1 1089/4885SMN1; SMN2 1176/4885 |
| US-10315991-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | TSHR 3518/4885ALDH1A1 1089/4885SMN1; SMN2 1176/4885 |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | TSHR 3518/4885ALDH1A1 1089/4885SMN1; SMN2 1176/4885 |
| US-20190202782-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | TSHR 3518/4885ALDH1A1 1089/4885SMN1; SMN2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.